Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAd3
- Development stage
- Unknown
- Lead developer
- Sabin Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics
01
Overview
CAd3 is a single-dose vaccine candidate developed by the Albert B. Sabin Vaccine Institute. It is based on a cAd3 platform and is designed to elicit immune responses against the Marburg virus glycoprotein. The development of this vaccine is supported by multi-million dollar contracts from the Biomedical Advanced Research and Development Authority (BARDA). It is currently in Phase 2 clinical trials for the prevention of Marburg virus infection.
- Other names
- cAd3 platform-based vaccine candidatecAd-3 platform-based vaccine candidatecAd 3 platform-based vaccine candidate
02
Targets
PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on CAd3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAd3.